Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the ...

2. Enhance NK cell proliferation and cytotoxicity Studies have shown a significant enhancement of NK cell proliferation and cytotoxicity with 4-1BBL, which triggers 4-1BB signaling to stimulate NK ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l ...

APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...

The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.